Optos urges skiers to consider eye health

Article

Optos is urging skiers to ensure they take care of their eyesight while on the slopes this winter, according to their latest press release.

Optos is urging skiers to ensure they take care of their eyesight while on the slopes this winter, according to their latest press release.

Skiing involves extended exposure to the sun's UV rays, which has been linked to eye damage such as cataracts and macular degeneration. Optos stresses it is important to wear the correct protective eyewear, as well as clothing and headgear.

The Optomap retinal imaging device can be utilised to capture an ultra-wide digital image to monitor retinal changes. This could help with earlier diagnosis of eye conditions caused by exposure to UV rays.

Roy Davis, CEO of Optos, commented, "The message on the importance of protecting our skin from over exposure to the sun has raised significant awareness in recent years. However, information about UV damage to the eyes is not as prevalent."

"Clinical research has found chronic effects from the sun can lead to photokeratitis commonly known as 'snow blindness'," he added, "Optometrists recommend UV protective ski goggles on the slopes and having a regular eye exam that includes a comprehensive retinal examination using technology such as Optomap.”

For further details please visit www.optomap.com

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.